Translating IL-6 biology into effective treatments

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

(2019) Kathrine Lederballe Grøn et al.   ANNALS OF THE RHEUMATIC DISEASES

Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition

(2019) Jose U. Scher et al.   Nature Reviews Rheumatology

Neutropenia During Tocilizumab Treatment Is Not Associated With Infection Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis

(2019) Manuela Pardeo et al.   JOURNAL OF RHEUMATOLOGY

Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis

(2019) Stephanie Finzel et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeting Interleukin-6 Signaling in Clinic

(2019) Sujin Kang et al.   IMMUNITY

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)

(2018) Yuko Kaneko et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

(2018) Peter C Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial

(2018) Violetta Opoka-Winiarska et al.   CLINICAL RHEUMATOLOGY

Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial

(2018) Kamal N. Bharucha et al.   JOURNAL OF RHEUMATOLOGY

Interleukin-6: designing specific therapeutics for a complex cytokine

(2018) Christoph Garbers et al.   NATURE REVIEWS DRUG DISCOVERY

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study

(2018) Seoyoung C. Kim et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab

(2018) Joel M. Kremer et al.   Arthritis & Rheumatology

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors

(2018) Xavier M Teitsma et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial

(2018) Yuko Kaneko et al.   ANNALS OF THE RHEUMATIC DISEASES

Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy

(2018) Kevin A. Hay   BRITISH JOURNAL OF HAEMATOLOGY

Takayasu arteritis: challenges in diagnosis and management

(2017) Esther S H Kim et al.   HEART

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

(2017) Daniel Aletaha et al.   LANCET

Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities

(2017) Christian Dejaco et al.   Nature Reviews Rheumatology

Pathogenesis of ankylosing spondylitis — recent advances and future directions

(2017) Vidya Ranganathan et al.   Nature Reviews Rheumatology

Trial of Tocilizumab in Giant-Cell Arteritis

(2017) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE

(2017) Jacques Morel et al.   RHEUMATOLOGY

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial

(2017) Christopher J Edwards et al.   RHEUMATOLOGY

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis

(2017) Mark C. Genovese et al.   Arthritis & Rheumatology

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study

(2017) Seoyoung C. Kim et al.   Arthritis & Rheumatology

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

(2016) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

(2016) Yuko Kaneko et al.   ANNALS OF THE RHEUMATIC DISEASES

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study

(2016) Valérie Devauchelle-Pensec et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System

(2016) T. Flaig et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study

(2016) Graeme Jones et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

(2016) Peter M Villiger et al.   LANCET

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

(2016) Dinesh Khanna et al.   LANCET

Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data

(2016) Maria Hoeltzenbein et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

(2016) Philip J. Mease et al.   Arthritis & Rheumatology

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

(2016) Brad H. Rovin et al.   Arthritis & Rheumatology

Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica

(2016) Lindsay Lally et al.   Arthritis & Rheumatology

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

(2015) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

(2015) Shumpei Yokota et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

(2015) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

(2015) Cem Gabay et al.   ANNALS OF THE RHEUMATIC DISEASES

Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan

(2015) K. Yamamoto et al.   JOURNAL OF RHEUMATOLOGY

Management of juvenile idiopathic arthritis: hitting the target

(2015) Claas Hinze et al.   Nature Reviews Rheumatology

Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources

(2015) Jeffrey R. Curtis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

(2015) Ryoko Sakai et al.   ARTHRITIS RESEARCH & THERAPY

Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial

(2015) Fabrizio De Benedetti et al.   Arthritis & Rheumatology

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study

(2014) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

(2014) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

(2014) Hermine I Brunner et al.   ANNALS OF THE RHEUMATIC DISEASES

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

(2014) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

(2014) J. San-Miguel et al.   BLOOD

Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights

(2014) Misato Hashizume et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis

(2014) Cécile Gaujoux-Viala et al.   JOINT BONE SPINE

Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan

(2014) S. Yokota et al.   JOURNAL OF RHEUMATOLOGY

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

(2014) Tomoyuki Imagawa et al.   Modern Rheumatology

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

(2013) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

(2013) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis

(2013) A. De Lauretis et al.   JOURNAL OF RHEUMATOLOGY

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan

(2013) T. Koike et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

(2013) Katinka Albrecht et al.   RHEUMATOLOGY INTERNATIONAL

Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature

(2013) Pierluigi Macchioni et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan

(2012) Shumpei Yokota et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

(2012) Yuko Shirota et al.   ANNALS OF THE RHEUMATIC DISEASES

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Pathogenesis of spondyloarthritis

(2012) Carmen Ambarus et al.   CURRENT OPINION IN RHEUMATOLOGY

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma

(2011) Shun Kitaba et al.   AMERICAN JOURNAL OF PATHOLOGY

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

(2011) T. Koike et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study

(2011) T. Takeuchi et al.   RHEUMATOLOGY

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Urinary IL-6: a marker for mesangial proliferative glomerulonephritis?

(2010) C. GORDON et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab

(2010) Y. Shima et al.   RHEUMATOLOGY

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

(2008) Minoru Fujimoto et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET

Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms

(2008) Larry W. Moreland et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: Implications for fatigue

(2007) Mary C. Davis et al.   BRAIN BEHAVIOR AND IMMUNITY